Contraceptive Steroids, age, and the cardiovascular system

Area of Science:

• Reproductive endocrinology
• Cardiovascular health
• Pharmacology

Background:

• Oral contraceptives (OCs) are associated with increased cardiovascular risks in women over 35.
• Estrogen's role in these risks has been debated, with some studies showing no increased risk in postmenopausal women on estrogen therapy.
• Emerging data suggest progestogen dosage may be a key factor in cardiovascular complications.

Purpose of the Study:

• To investigate the relationship between progestogen dosage in oral contraceptives and cardiovascular risk.
• To re-evaluate the role of estrogen versus progestogen in OC-related cardiovascular complications.
• To determine optimal steroid dosages for oral contraception in women over 35.

Main Methods:

• Review of clinical data on oral contraceptive use and cardiovascular events.
• Analysis of the impact of different progestogen and estrogen doses on lipid profiles, specifically high-density lipoprotein (HDL) cholesterol.
• Comparative analysis of risk in OC users versus non-users, and postmenopausal hormone therapy users.

Main Results:

• Clinical data indicate a dose-dependent decrease in high-density lipoprotein cholesterol with increasing progestogen levels.
• Evidence suggests a correlation between progestogen dosage and circulatory disease morbidity.
• Postmenopausal women on estrogen therapy alone or with minimal progestogen did not show increased cardiovascular risk.

Conclusions:

• Progestogen dosage appears to be a significant factor in the cardiovascular risks associated with oral contraceptives.
• The smallest effective doses of both estrogen and progestogen should be used in oral contraceptive formulations.
• Particular attention to lower steroid doses is warranted for women over 35 using oral contraception.